Context Therapeutics Inc. (NASDAQ:CNTX - Free Report) - Analysts at William Blair issued their Q1 2025 EPS estimates for shares of Context Therapeutics in a report issued on Monday, April 21st. William Blair analyst M. Phipps anticipates that the company will post earnings of ($0.05) per share for the quarter. William Blair currently has a "Outperform" rating on the stock. The consensus estimate for Context Therapeutics' current full-year earnings is ($0.51) per share. William Blair also issued estimates for Context Therapeutics' Q2 2025 earnings at ($0.06) EPS, Q3 2025 earnings at ($0.07) EPS, Q4 2025 earnings at ($0.08) EPS, FY2025 earnings at ($0.26) EPS, FY2026 earnings at ($0.31) EPS, FY2027 earnings at ($0.40) EPS and FY2028 earnings at ($0.55) EPS.
CNTX has been the subject of several other reports. JMP Securities assumed coverage on Context Therapeutics in a research note on Wednesday, January 8th. They set an "outperform" rating and a $4.00 target price for the company. Citizens Jmp upgraded shares of Context Therapeutics to a "strong-buy" rating in a research report on Wednesday, January 8th. HC Wainwright reaffirmed a "buy" rating and set a $5.00 price objective on shares of Context Therapeutics in a report on Friday, March 21st. Finally, D. Boral Capital reissued a "buy" rating and set a $9.00 target price on shares of Context Therapeutics in a research note on Wednesday, April 9th. Seven investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Buy" and a consensus target price of $6.17.
View Our Latest Stock Analysis on CNTX
Context Therapeutics Price Performance
NASDAQ CNTX traded down $0.06 during trading hours on Wednesday, reaching $0.94. The company's stock had a trading volume of 56,388 shares, compared to its average volume of 409,299. Context Therapeutics has a 1-year low of $0.55 and a 1-year high of $2.75. The company's 50-day moving average is $0.78 and its two-hundred day moving average is $1.20. The firm has a market capitalization of $84.32 million, a price-to-earnings ratio of -1.03 and a beta of 2.18.
Context Therapeutics (NASDAQ:CNTX - Get Free Report) last issued its quarterly earnings data on Thursday, March 20th. The company reported ($0.04) earnings per share for the quarter, topping analysts' consensus estimates of ($0.05) by $0.01.
Hedge Funds Weigh In On Context Therapeutics
Hedge funds and other institutional investors have recently modified their holdings of the business. State Street Corp lifted its stake in Context Therapeutics by 21.5% in the 3rd quarter. State Street Corp now owns 111,907 shares of the company's stock worth $219,000 after purchasing an additional 19,800 shares in the last quarter. Franklin Resources Inc. purchased a new position in Context Therapeutics during the third quarter worth approximately $3,689,000. Blue Owl Capital Holdings LP boosted its stake in Context Therapeutics by 17.5% during the fourth quarter. Blue Owl Capital Holdings LP now owns 6,357,928 shares of the company's stock worth $6,676,000 after buying an additional 946,638 shares during the last quarter. Landscape Capital Management L.L.C. purchased a new stake in Context Therapeutics in the 4th quarter valued at $94,000. Finally, Clear Harbor Asset Management LLC increased its stake in shares of Context Therapeutics by 60.6% in the 4th quarter. Clear Harbor Asset Management LLC now owns 57,804 shares of the company's stock worth $61,000 after acquiring an additional 21,804 shares during the last quarter. 14.03% of the stock is owned by hedge funds and other institutional investors.
About Context Therapeutics
(
Get Free Report)
Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.
Read More
Before you consider Context Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Context Therapeutics wasn't on the list.
While Context Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
